Product Code: 978-1-68038-086-6
The global molecular diagnostics market size is expected to reach USD 19.8 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 9.1% over the forecast period. Increasing prevalence of infectious diseases, such as human papillomavirus and influenza, is expected to be the primary force driving the market.
Instruments such as PCR and next generation sequencing platforms are widely preferred by central laboratories and diagnostic institutes due to rapid nature of these tests in delivering quick and reliable results and high volume of diagnostic procedures in this segment. Associated advantages including user-friendly nature of these tests and quick healthcare delivery are estimated to propel the point-of-care segment growth.
In underdeveloped regions of Africa and Nigeria, other infections such as HIV and tuberculosis are increasing at a high rate since the last few years. This is estimated to increase demand for early and accurate diagnostic techniques to curb their surge.
Molecular testing tools provide clinicians with better alternatives to detect countless infectious bacteria, virus, and pathogens in a short time while delivering highly accurate results. Initiatives led by organizations such as the WHO to conduct diagnostic programs in regions with high risk areas are estimated to be a high rendering driver.
Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses, is also expected to widen the client base for the molecular diagnostics market. Moreover, high adoption of unhealthy lifestyles resulting in a large patient count afflicted with chronic diseases such as diabetes and cardiovascular disorders is projected to positively impact the growth.
Rising healthcare spending, increasing awareness among patients, and expansion of R&D activities related to drug discovery and development are expected to drive the market in North America and Europe. Rising demand for improved diagnostic technologies employed for the prevention of epidemics, unaddressed clinical needs, and recent activities by key players targeting expansion in this region are the major factors supporting the market growth in Asia Pacific.
Key players are advancing strategic collaborations with major technology-based companies and diagnostic centers and tapping developing regions in an attempt to increase their market share and attain stability.
Further key findings from the study suggest:
On the basis of product, reagents were the largest revenue generating segment in 2018 owing to their elevated usage rates. Reagents are key products used in academic and research institutes to perform various molecular biology protocols, further contributing towards the growth of this segment
Based on test location, central laboratories led the market with the largest market share in 2018 owing to their established base in the remote and developing regions. The point-of-care segment is expected to witness the fastest growth over the forecast period
On the basis of application, infectious diseases dominated the overall molecular diagnostics market in 2018. The oncology application segment is expected to exhibit a CAGR of around 11.8% over the forecast period due to rising awareness among people as well as healthcare professionals pertaining to cancer diagnosis
Based on technology, the polymerase chain reaction (PCR) dominated the market in terms of revenue in 2018, attributed to growing applications of multiplex PCR over the conventional PCR procedure and introduction of easy-to-use PCR handling kits
North America emerged as the largest regional segment in 2018, followed by Europe, primarily driven by well-established healthcare infrastructure. Asia Pacific is expected witness the fastest growth over the forecast period
Some of the major players are Novartis AG (Grifols); Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Alere, Inc.; Danaher Corporation; BioMerieux SA; Sysmex Corporation; Becton; Dickinson and Company; Johnson & Johnson Services, Inc.; Bio-Rad Laboratories, Inc.; Bayer AG, Qiagen; Hologic, Inc. (Gen Probe); Cepheid; F. Hoffmann-La Roche Ltd; and Dako.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources & Third party perspectives
- 1.3.4. Primary research
- 1.4. Information Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Data Visualization
- 1.6. Data Validation & Publishing
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Molecular Diagnostics Market Variables, Trends & Scope
- 3.1. Molecular Diagnostics Market Lineage outlook
- 3.1.1. IVD market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Regulatory Framework
- 3.3.1. Reimbursement framework
- 3.3.2. Standards & compliances
- 3.4. Market Dynamics
- 3.4.1. Market driver analysis
- 3.4.1.1. Increase in geriatric population
- 3.4.1.2. Introduction of technologically advanced products
- 3.4.1.3. Increase in demand for point-of-care facilities
- 3.4.1.4. Growing prevalence of target diseases
- 3.4.1.5. Increasing external funding for R&D
- 3.4.2. Market restraint analysis
- 3.4.2.1. Presence of ambiguous regulatory framework
- 3.4.2.2 High prices of molecular diagnostics tests
- 3.5. Molecular Diagnostics Market Analysis Tools
- 3.5.1. Industry analysis - Porter's
- 3.5.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
- 3.5.1.2. Buyer power (Low due to limited number of established providers)
- 3.5.1.3. Substitution threat (Moderate due to high prices of molecular tests)
- 3.5.1.4. New entrants' threat (Moderate due to manufacturing capital is high)
- 3.5.1.5. Competitive rivalry (High due to presence of many key players)
- 3.5.2. PESTEL analysis
- 3.5.2.1. Political landscape
- 3.5.2.2. Environmental landscape
- 3.5.2.3. Social landscape
- 3.5.2.4. Technology landscape
- 3.5.2.5. Legal landscape
- 3.5.3. Major deals & strategic alliances analysis
- 3.5.3.1. Joint ventures
- 3.5.3.2. Mergers & acquisitions
- 3.5.3.3. Licensing & partnership
- 3.5.3.4. Technology collaborations
- 3.5.3.5. Strategic divestments
Chapter 4. Molecular Diagnostics Market - Competitive Analysis
- 4.1. Recent Developments & Impact Analysis, by Key Market Participants
- 4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
- 4.3. Vendor Landscape
- 4.3.1. List of key distributors and channel partners
- 4.3.2. Key company market share analysis, 2018
- 4.4. Public Companies
- 4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
- 4.4.2. Company market share
- 4.4.3. Competitive dashboard analysis
- 4.4.4. Market differentiators
- 4.4.5. Synergy analysis: Major deals & strategic alliances
- 4.5. Private Companies
- 4.5.1. List of key emerging companies
- 4.5.2. Regional network map
- 4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Molecular Diagnostics Market: Product Estimates & Trend Analysis
- 5.1. Definitions & Scope
- 5.2. Product Market Share Analysis, 2018 & 2026
- 5.3. Molecular Diagnostics Market, by Product, 2014 to 2026
- 5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
- 5.4.1. Instruments
- 5.4.1.1 Instrument market, 2014 - 2026 (USD Million)
- 5.4.2. Reagents
- 5.4.2.1 Reagents market, 2014 - 2026 (USD Million)
- 5.4.3. Others
- 5.4.3.1 Others market, 2014 - 2026 (USD Million)
Chapter 6. Molecular Diagnostics Market: Test Location Estimates & Trend Analysis
- 6.1. Definitions & Scope
- 6.2. Test Location Market Share Analysis, 2018 & 2026
- 6.3. Molecular Diagnostics Market, by Test Location, 2014 to 2026
- 6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
- 6.4.1. Point of care
- 6.4.1.1 Point of care market, 2014 - 2026 (USD Million)
- 6.4.2. Self-test or OTC
- 6.4.2.1 Self-test or OTC market, 2014 - 2026 (USD Million)
- 6.4.3. Central laboratories
- 6.4.3.1 Central laboratories market, 2014 - 2026 (USD Million)
Chapter 7. Molecular Diagnostics Market: Technology Estimates & Trend Analysis
- 7.1. Definitions & Scope
- 7.2. Technology Market Share Analysis, 2018 & 2026
- 7.3. Molecular Diagnostics Market, by Technology, 2014 to 2026
- 7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
- 7.4.1. PCR
- 7.4.1.1 PCR market, 2014 - 2026 (USD Million)
- 7.4.1.2 Multiplex PCR
- 7.4.1.2.1 Multiplex PCR market, 2014 - 2026 (USD Million)
- 7.4.1.3 Others
- 7.4.1.3.1 Others market, 2014 - 2026 (USD Million)
- 7.4.2. ISH
- 7.4.2.1 ISH market, 2014 - 2026 (USD Million)
- 7.4.3. INAAT
- 7.4.3.1 INAAT market, 2014 - 2026 (USD Million)
- 7.4.4. Chips and microarrays
- 7.4.4.1 Chips and microarrays market, 2014 - 2026 (USD Million)
- 7.4.5. Mass spectrometry
- 7.4.5.1 Mass spectrometry market, 2014 - 2026 (USD Million)
- 7.4.6. Sequencing
- 7.4.6.1 Sequencing market, 2014 - 2026 (USD Million)
- 7.4.7. TMA
- 7.4.7.1 TMA market, 2014 - 2026 (USD Million)
- 7.4.8. Others
- 7.4.8.1 Others market, 2014 - 2026 (USD Million)
- 7.5. Technology Markets, by Product, 2014 to 2026:
- 7.5.1. PCR
- 7.5.1.1 Instruments
- 7.5.1.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.1.2 Reagents
- 7.5.1.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.1.3 Others
- 7.5.1.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.2. ISH
- 7.5.2.1 Instruments
- 7.5.2.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.2.2. Reagents
- 7.5.2.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.2.3 Others
- 7.5.2.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.3. INAAT
- 7.5.3.1 Instruments
- 7.5.3.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.3.2. Reagents
- 7.5.3.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.3.3 Others
- 7.5.3.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.4. Chips and microarrays
- 7.5.4.1 Instruments
- 7.5.4.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.4.2. Reagents
- 7.5.4.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.4.3 Others
- 7.5.4.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.5. Mass spectrometry
- 7.5.5.1 Instruments
- 7.5.5.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.5.2. Reagents
- 7.5.5.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.5.3 Others
- 7.5.5.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.6. Sequencing
- 7.5.6.1 Instruments
- 7.5.6.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.6.2. Reagents
- 7.5.6.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.6.3 Others
- 7.5.6.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.7. TMA
- 7.5.7.1 Instruments
- 7.5.7.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.7.2. Reagents
- 7.5.7.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.7.3 Others
- 7.5.7.3.1 Others market, 2014 - 2026 (USD Million)
- 7.5.8. Others
- 7.5.8.1 Instruments
- 7.5.8.1.1 Instrument market, 2014 - 2026 (USD Million)
- 7.5.8.2. Reagents
- 7.5.8.2.1 Reagents market, 2014 - 2026 (USD Million)
- 7.5.8.3 Others
- 7.5.8.3.1 Others market, 2014 - 2026 (USD Million)
Chapter 8. Molecular Diagnostics Market: Application Estimates & Trend Analysis
- 8.1. Definitions & Scope
- 8.2. Application Market Share Analysis, 2018 & 2026
- 8.3. Molecular Diagnostics Market, by Application, 2014 to 2026
- 8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
- 8.4.1. Oncology
- 8.4.1.1 Oncology market, 2014 - 2026 (USD Million)
- 8.4.1.2 Breast cancer
- 8.4.1.2.1 Breast cancer market, 2014 - 2026 (USD Million)
- 8.4.1.3 Prostate cancer
- 8.4.1.3.1 Prostate cancer market, 2014 - 2026 (USD Million)
- 8.4.1.4 Colorectal cancer
- 8.4.1.4.1 Colorectal cancer market, 2014 - 2026 (USD Million)
- 8.4.1.5 Cervical cancer
- 8.4.1.5.1 Cervical cancer market, 2014 - 2026 (USD Million)
- 8.4.1.6 Kidney cancer
- 8.4.1.6.1 Kidney cancer market, 2014 - 2026 (USD Million)
- 8.4.1.7 Liver cancer
- 8.4.1.7.1 Liver cancer market, 2014 - 2026 (USD Million)
- 8.4.1.8 Blood cancer
- 8.4.1.8.1 Blood cancer market, 2014 - 2026 (USD Million)
- 8.4.1.9 Lung cancer
- 8.4.1.9.1 Lung cancer market, 2014 - 2026 (USD Million)
- 8.4.1.10 Others
- 8.4.1.10.1 Others market, 2014 - 2026 (USD Million)
- 8.4.2. Pharmacogenomics
- 8.4.2.1 Pharmacogenomics market, 2014 - 2026 (USD Million)
- 8.4.3. Infectious disease
- 8.4.3.1 Infectious disease market, 2014 - 2026 (USD Million)
- 8.4.3.2 MRSA
- 8.4.3.2.1 MRSA market, 2014 - 2026 (USD Million)
- 8.4.3.3 Clostridium difficile
- 8.4.3.3.1 Clostridium difficile market, 2014 - 2026 (USD Million)
- 8.4.3.4 Vancomycin-resistant enterococci
- 8.4.3.4.1 Vancomycin-resistant enterococci market, 2014 - 2026 (USD Million)
- 8.4.3.5 Carbapenem-resistant bacteria
- 8.4.3.5.1 Carbapenem-resistant bacteria, 2014 - 2026 (USD Million)
- 8.4.3.6 Flu
- 8.4.3.6.1 Flu market, 2014 - 2026 (USD Million)
- 8.4.3.7 Respiratory syncytial virus (RSV)
- 8.4.3.7.1 Respiratory syncytial virus (RSV) market, 2014 - 2026 (USD Million)
- 8.4.3.8 Candida
- 8.4.3.8.1 Candida market, 2014 - 2026 (USD Million)
- 8.4.3.9 Tuberculosis and drug-resistant TBA
- 8.4.3.9.1 Tuberculosis and drug-resistant TBA market, 2014 - 2026 (USD Million)
- 8.4.3.10 Meningitis
- 8.4.3.10.1 Meningitis market, 2014 - 2026 (USD Million)
- 8.4.3.11 Gastrointestinal panel testing
- 8.4.3.11.1 Gastrointestinal panel testing market, 2014 - 2026 (USD Million)
- 8.4.3.12 Chlamydia
- 8.4.3.12.1 Chlamydia market, 2014 - 2026 (USD Million)
- 8.4.3.13 Gonorrhea
- 8.4.3.13.1 Gonorrhea market, 2014 - 2026 (USD Million)
- 8.4.3.14 HIV
- 8.4.3.14.1 HIV market, 2014 - 2026 (USD Million)
- 8.4.3.15 Hepatitis C
- 8.4.3.15.1 Hepatitis C market, 2014 - 2026 (USD Million)
- 8.4.3.16 Hepatitis B
- 8.4.3.16.1 Hepatitis B market, 2014 - 2026 (USD Million)
- 8.4.3.17 Other
- 8.4.3.17.1 Other market, 2014 - 2026 (USD Million)
- 8.4.4. Genetic testing
- 8.4.4.1 Genetic testing market, 2014 - 2026 (USD Million)
- 8.4.4.2 Newborn screening
- 8.4.4.2.1 Newborn screening market, 2014 - 2026 (USD Million)
- 8.4.4.3 Predictive and presymptomatic testing
- 8.4.4.3.1 Predictive and presymptomatic testing market, 2014 - 2026 (USD Million)
- 8.4.4.4 Others
- 8.4.4.4.1 Others market, 2014 - 2026 (USD Million)
- 8.4.5. Neurological disease
- 8.4.5.1 Neurological disease market, 2014 - 2026 (USD Million)
- 8.4.6. Cardiovascular disease
- 8.4.6.1 Cardiovascular disease market, 2014 - 2026 (USD Million)
- 8.4.7. Microbiology
- 8.4.7.1 Microbiology market, 2014 - 2026 (USD Million)
- 8.4.8. Others
- 8.4.8.1 Others market, 2014 - 2026 (USD Million)
Chapter 9 Molecular Diagnostics Market: Regional Estimates & Trend Analysis, by Product, Test Location, Technology, & Application
- 9.1 Molecular Diagnostics Market: Regional Movement Analysis, 2018 & 2026
- 9.2 Molecular Diagnostics Market: Leading Players, 2018:
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
- 9.3.1. North America
- 9.3.2. Europe
- 9.3.3. Asia Pacific
- 9.3.4. Latin America
- 9.3.5. Middle East & Africa
- 9.4 North America
- 9.4.1 North America market, 2014 - 2026 (USD Million)
- 9.4.2 U.S.
- 9.4.2.1 U.S. market, 2014 - 2026 (USD Million)
- 9.4.3 Canada
- 9.4.3.1 Canada market, 2014 - 2026 (USD Million)
- 9.5. Europe
- 9.5.1 Europe market, 2014 - 2026 (USD Million)
- 9.5.2 U.K.
- 9.5.2.1 U.K. market, 2014 - 2026 (USD Million)
- 9.5.3 Germany
- 9.5.3.1 Germany market, 2014 - 2026 (USD Million)
- 9.5.4 France
- 9.5.4.1 France market, 2014 - 2026 (USD Million)
- 9.5.5 Spain
- 9.5.5.1 Spain market, 2014 - 2026 (USD Million)
- 9.5.6 Italy
- 9.5.6.1 Italy market, 2014 - 2026 (USD Million)
- 9.5.7 Belgium
- 9.5.7.1 Belgium market, 2014 - 2026 (USD Million)
- 9.5.8 Switzerland
- 9.5.8.1 Switzerland market, 2014 - 2026 (USD Million)
- 9.5.9 Netherlands
- 9.5.9.1 Netherlands market, 2014 - 2026 (USD Million)
- 9.5.10 Poland
- 9.5.10.1 Poland market, 2014 - 2026 (USD Million)
- 9.5.11 Austria
- 9.5.11.1 Austria market, 2014 - 2026 (USD Million)
- 9.5.12 Greece
- 9.5.12.1 Greece market, 2014 - 2026 (USD Million)
- 9.5.13 Sweden
- 9.5.13.1 Sweden market, 2014 - 2026 (USD Million)
- 9.5.14 Turkey
- 9.5.14.1 Turkey market, 2014 - 2026 (USD Million)
- 9.5.15 Finland
- 9.5.15.1 Finland market, 2014 - 2026 (USD Million)
- 9.6 Asia Pacific
- 9.6.1 Asia Pacific market, 2014 - 2026 (USD Million)
- 9.6.2 Japan
- 9.6.2.1 Japan market, 2014 - 2026 (USD Million)
- 9.6.3 China
- 9.6.3.1 China market, 2014 - 2026 (USD Million)
- 9.6.4 India
- 9.6.4.1 India market, 2014 - 2026 (USD Million)
- 9.6.5 Australia
- 9.6.5.1 Australia market, 2014 - 2026 (USD Million)
- 9.6.6 New Zealand
- 9.6.6.1 New Zealand market, 2014 - 2026 (USD Million)
- 9.6.7 Sri Lanka
- 9.6.7.1 Sri Lanka market, 2014 - 2026 (USD Million)
- 9.6.8 Malaysia
- 9.6.8.1 Malaysia market, 2014 - 2026 (USD Million)
- 9.6.9 Thailand
- 9.6.9.1 Thailand market, 2014 - 2026 (USD Million)
- 9.6.10 Vietnam
- 9.6.10.1 Vietnam market, 2014 - 2026 (USD Million)
- 9.6.11 Singapore
- 9.6.11.1 Singapore market, 2014 - 2026 (USD Million)
- 9.7 Latin America
- 9.7.1 Latin America market, 2014 - 2026 (USD Million)
- 9.7.2 Brazil
- 9.7.2.1 Brazil market, 2014 - 2026 (USD Million)
- 9.7.3 Mexico
- 9.7.3.1 Mexico market, 2014 - 2026 (USD Million)
- 9.7.4 Colombia
- 9.7.4.1 Colombia market, 2014 - 2026 (USD Million)
- 9.7.5 Chile
- 9.7.5.1 Chile market, 2014 - 2026 (USD Million)
- 9.7.6 Peru
- 9.7.6.1 Peru market, 2014 - 2026 (USD Million)
- 9.7.7 Argentina
- 9.7.7.1 Argentina market, 2014 - 2026 (USD Million)
- 9.8 MEA
- 9.8.1 MEA market, 2014 - 2026 (USD Million)
- 9.8.2 South Africa
- 9.8.2.1 South Africa market, 2014 - 2026 (USD Million)
- 9.8.3 Saudi Arabia
- 9.8.3.1 Saudi Arabia market, 2014 - 2026 (USD Million)
- 9.8.4 Jordan
- 9.8.4.1 Jordan Arabia market, 2014 - 2026 (USD Million)
- 9.8.5 UAE
- 9.8.5.1 UAE Arabia market, 2014 - 2026 (USD Million)
- 9.8.6 Qatar
- 9.8.6.1 Qatar Arabia market, 2014 - 2026 (USD Million)
- 9.8.7 Nigeria
- 9.8.7.1 Nigeria Arabia market, 2014 - 2026 (USD Million)
- 9.8.8 Egypt
- 9.8.8.1 Egypt Arabia market, 2014 - 2026 (USD Million)
Chapter 10 Competitive Landscape
- 10.1 Strategy Framework
- 10.2 Heat Map Analysis of Private Companies
- 10.2.1 Company size
- 10.2.2 Distribution network
- 10.2.3 Product portfolio
- 10.2.4 Segment coverage
- 10.2.5 Geographic presence
- 10.2.6 Collaborations
- 10.2.7 Conclusion
- 10.3 Abbott
- 10.3.1 Company overview
- 10.3.2 Financial performance
- 10.3.3 Product benchmarking
- 10.3.4 Strategic initiatives
- 10.4 Becton, Dickinson and Company
- 10.4.1 Company overview
- 10.4.2 Financial performance
- 10.4.3 Product benchmarking
- 10.4.4 Strategic initiatives
- 10.5 bioMerieux SA
- 10.5.1 Company overview
- 10.5.2 Financial performance
- 10.5.3 Product benchmarking
- 10.5.4 Strategic initiatives
- 10.6 Bio-Rad Laboratories, Inc.
- 10.6.1 Company overview
- 10.6.2 Financial performance
- 10.6.3 Product benchmarking
- 10.6.4 Strategic initiatives
- 10.7 Dako
- 10.7.1 Company overview
- 10.7.2 Financial performance
- 10.7.3 Product benchmarking
- 10.7.4 Strategic initiatives
- 10.8 Danaher Corporation
- 10.8.1 Company overview
- 10.8.2 Financial performance
- 10.8.3 Product benchmarking
- 10.8.4 Strategic initiatives
- 10.9 Hologic, Inc. (Gen Probe)
- 10.9.1 Company overview
- 10.9.2 Financial performance
- 10.9.3 Product benchmarking
- 10.9.4 Strategic initiatives
- 10.10 Illumina, Inc.
- 10.10.1 Company overview
- 10.10.2 Product benchmarking
- 10.10.3 Strategic initiatives
- 10.11 Johnson & Johnson Services, Inc
- 10.11.1 Company Overview
- 10.11.2 Financial performance
- 10.11.3 Product benchmarking
- 10.11.4 Strategic initiatives
- 10.12 Novartis (Grifols)
- 10.12.1 Company overview
- 10.12.2 Financial performance
- 10.12.3 Product benchmarking
- 10.12.4 Strategic initiatives
- 10.13 Qiagen
- 10.13.1 Company overview
- 10.13.2 Financial overview
- 10.13.3 Product benchmarking
- 10.13.4 Strategic initiatives
- 10.14 Roche Diagnostics
- 10.14.1 Company overview
- 10.14.2 Financial overview
- 10.14.3 Product benchmarking
- 10.14.4 Strategic initiatives
- 10.15 Siemens Healthcare Private Limited
- 10.15.1 Company overview
- 10.15.2 Financial performance
- 10.15.3 Product benchmarking
- 10.15.4 Strategic initiatives
- 10.16 Sysmex Corporation
- 10.16.1 Company overview
- 10.16.2 Financial performance
- 10.16.3 Products benchmarking
- 10.16.4 Strategic initiatives
コンパニオンアニマル診断市場：技術別（臨床生化学、尿検査、免疫診断、血液学、分子診断）、用途別（臨床病理学、細菌学、寄生虫学）、動物別（犬、猫）、エンドユーザー別、2024年までの予測
世界における体外診断 (IVD) 臨床ラボサービス市場の動向・予測
がん分子診断の世界市場：2019年〜2023年
世界におけるIVD感染症市場の規模、シェア、動向分析：試験部位別、製品別、用途別、技術別（免疫化学、分子診断）、セグメント予測
分子診断試薬の世界市場
バイオテクノロジーにおける分子診断の世界市場：成長、動向、予測
分子診断の世界市場：技術・製品・用途・エンドユーザー
分子診断の世界市場 - 分析・予測 (2018-2028年)：感染症、遺伝子検査、血液ドナースクリーニング、癌、ヒト白血球型抗原 (HLA) 検査、NIPT (非侵襲性出生前検査) 、コンパニオン診断、リキッドバイオプシー
分子診断の世界市場の分析と予測
世界の分子診断市場：産業分析と見通し
